Smoking Cessation

Cigarette smoke delivers a bolus of nicotine to the brain within roughly 10 seconds of inhalation, faster than intravenous injection. This guide is a physician's evidence-based look at nicotine addiction, the FDA-approved medications that work, combination therapy, behavioral support, and what the evidence actually says about quitting for good in 2026. Every material claim is cited to a primary source.

Why nicotine is addictive

Cigarette smoke delivers a bolus of nicotine to the brain within roughly 10 seconds of inhalation, faster than intravenous injection. Nicotine binds to α4β2 nicotinic acetylcholine receptors in the ventral tegmental area, triggering dopamine release in the nucleus accumbens, the same reward circuit implicated in cocaine and opioid use. With repeated exposure, the number of these receptors upregulates, and the brain adapts to expect continuous nicotine delivery.^[2]

This adaptation is what makes withdrawal so difficult. When nicotine falls below the level the brain now considers baseline, a stereotyped withdrawal syndrome emerges within hours:

• Intense cravings ("urges to smoke")
• Irritability, anxiety, and restlessness
• Difficulty concentrating
• Increased appetite and weight gain
• Sleep disturbance and vivid dreams
• Depressed mood

Withdrawal symptoms peak within 3 days of the last cigarette and typically resolve within 2 to 4 weeks. However, conditioned cravings, the urges triggered by morning coffee, alcohol, stress at work, or specific locations, can persist for months to years. Every cue that was ever paired with a cigarette becomes a potential trigger. This is why quitting is not simply a matter of "willpower": it is a battle against a rewired reward system, and it is exactly why pharmacotherapy that blunts withdrawal is so effective.

The health case for quitting

Cigarette smoking causes approximately 480,000 deaths per year in the United States and is causally linked to cancers of the lung, larynx, esophagus, bladder, pancreas, kidney, cervix, and blood, as well as coronary heart disease, stroke, chronic obstructive pulmonary disease (COPD), abdominal aortic aneurysm, and type 2 diabetes.^[10]

The clinical benefits of quitting begin within minutes and continue for decades:

• Within 20 minutes: heart rate and blood pressure begin to normalize
• Within 12 hours: blood carbon monoxide levels return to normal
• Within 2 weeks to 3 months: lung function and circulation improve measurably
• Within 1 year: excess risk of coronary heart disease is roughly halved
• Within 5 to 10 years: stroke risk approaches that of a never-smoker
• Within 10 to 15 years: lung cancer death risk falls to about half that of continued smokers

Approximately 34 million U.S. adults still smoke cigarettes, and adults who quit before age 40 avoid nearly all of the excess mortality associated with continued smoking. Quitting by ages 45 to 54 adds about 6 years of life expectancy; quitting by 55 to 64 adds about 4 years.^[2]

What's Changed in 2024 to 2026

Smoking cessation science is not standing still. Several updates from the past two years change how a clinician (and a patient) should think about a modern quit plan.

Varenicline is back in full supply and now generic. After a 2021 recall for nitrosamine impurities, brand Chantix was discontinued in the U.S., but generic varenicline has been widely available since 2022 and cash prices at major U.S. pharmacies are typically $70 to $130 for a 12-week course as of 2026, a fraction of the pre-generic price. This substantially changes the cost-benefit calculation for what remains the most effective single-agent therapy.

Boxed warning permanently retired. The FDA's December 2016 removal of varenicline's neuropsychiatric boxed warning has now been in place for nearly a decade, and no signal has re-emerged. In routine practice, varenicline is considered appropriate for patients with stable depression, anxiety, bipolar disorder, and schizophrenia.^[4]

Combination NRT is now the OTC standard of care. High-certainty Cochrane evidence (16 trials, 12,169 participants) confirms that patch plus a fast-acting form (gum or lozenge) outperforms any single NRT form (RR 1.27).^[5] Combined with the price of NRT at warehouse retailers, this is often the most accessible high-efficacy option.

Cytisinicline NDA delayed, Complete Response Letter (June 22, 2026). The FDA issued a Complete Response Letter (CRL) to Achieve Life Sciences on June 22, 2026, citing outstanding cGMP observations at a former third-party manufacturing facility and incomplete final product labeling by the PDUFA action date. Critically, the FDA identified no deficiencies regarding the clinical efficacy or safety of cytisinicline.^[15] Achieve has since transferred manufacturing to Adare Pharma Solutions in the United States, completed the analytical method transfer, and manufactured its first engineering batch. The company plans to resubmit the NDA in Q4 2026 with potential FDA approval in H1 2027. Two Phase 3 U.S. trials (ORCA-2 and ORCA-3) previously showed 4- to 6-fold higher odds of continuous abstinence at 24 weeks compared with placebo and a favorable side-effect profile compared with varenicline.^[8] If eventually approved, cytisinicline would be the first new prescription cessation medication in the United States in nearly two decades.

E-cigarette evidence has continued to accumulate. The NEJM Hajek trial (2019) showed e-cigarettes outperformed NRT for 1-year abstinence when both were paired with behavioral support (18.0% vs 9.9%).^[6] The USPSTF still gives e-cigarettes an "I" (insufficient evidence) statement due to long-term safety questions and product heterogeneity.^[1] The consensus 2026 position: e-cigarettes are not first-line, but for a smoker who has failed traditional cessation, a full switch, followed by tapering off the e-cigarette, is a reasonable harm-reduction strategy.

Telehealth prescribing is fully normalized. Varenicline, bupropion, and prescription NRT (inhaler, nasal spray) are all non-controlled substances and can be prescribed after a synchronous telehealth visit in all 50 U.S. states. No in-person visit is required for a straightforward quit attempt.

Decision Framework: OTC, Prescription, or Combination

First-Line Medications

The three FDA-approved first-line pharmacotherapies for smoking cessation are varenicline, bupropion sustained-release, and nicotine replacement therapy in five forms. All three are more effective than placebo. All three can be combined with behavioral support for additive benefit. USPSTF pooled risk ratios versus minimal support: varenicline 2.24, bupropion 1.64, NRT 1.55, combined pharmacotherapy plus behavioral 1.83.^[1]

Varenicline (generic; formerly Chantix)

How it works: partial agonist at the α4β2 nicotinic acetylcholine receptor. It partially stimulates the receptor to reduce cravings and withdrawal, while simultaneously blocking nicotine from binding, so smoking during treatment feels less rewarding.

Efficacy: the most effective single-agent cessation medication currently on the U.S. market. In EAGLES, 6-month continuous abstinence was 21.8% versus 9.4% with placebo.^[3] USPSTF pooled RR 2.24.^[1]

Standard dosing (12 weeks): start medication 1 week before your quit date. Days 1–3: 0.5 mg once daily. Days 4–7: 0.5 mg twice daily. Day 8 onward: 1 mg twice daily. An additional 12 weeks can be prescribed to reduce relapse in patients who have successfully quit.

Common side effects: nausea (approximately 30%, take with food and a full glass of water), abnormal or vivid dreams, insomnia, headache, constipation. Nausea is usually manageable and improves within the first 2 weeks.

Safety notes: the FDA removed the boxed warning for serious neuropsychiatric events in December 2016 based on EAGLES data showing no excess events versus placebo.^[4] Patients should still be counseled to report new or worsening mood changes, since nicotine withdrawal itself can transiently worsen mood.

Cost in 2026: generic varenicline typically runs $70 to $130 for a 12-week course at U.S. pharmacies with common discount cards or coupons.

Bupropion sustained-release (Zyban, Wellbutrin SR)

How it works: inhibits reuptake of dopamine and norepinephrine and acts as a non-competitive antagonist at nicotinic receptors. Originally developed as an antidepressant, later shown to independently aid smoking cessation.

Efficacy: in EAGLES, 6-month abstinence 16.2%.^[3] USPSTF pooled RR 1.64.^[1] Comparable to nicotine patch as monotherapy.

Standard dosing (7–12 weeks): start 1–2 weeks before quit date. Days 1–3: 150 mg once daily. Day 4 onward: 150 mg twice daily. Doses must be at least 8 hours apart (a 4 PM dose can cause insomnia; morning + early afternoon is often better).

Common side effects: insomnia, dry mouth, headache, agitation, decreased appetite.

Contraindications:

• History of seizure disorder (bupropion lowers the seizure threshold)
• Current or prior eating disorder (bulimia or anorexia nervosa)
• Abrupt discontinuation of alcohol, benzodiazepines, or antiepileptics
• Use of MAO inhibitors within 14 days
• Severe hepatic impairment (dose reduction required)

Special utility: bupropion is often the preferred first-line agent in patients with comorbid depression, since it provides both cessation and antidepressant activity.

Nicotine replacement therapy (NRT)

How it works: replaces the nicotine from cigarettes at controlled, non-toxic doses, without the combustion byproducts (tar, carbon monoxide, polycyclic aromatic hydrocarbons) that cause the vast majority of smoking's harm. NRT blunts withdrawal so the behavioral change becomes possible.

Efficacy: USPSTF pooled RR 1.55.^[1] In EAGLES, nicotine patch produced 15.7% 6-month abstinence.^[3] Combination NRT, patch plus a fast-acting form, is superior to any single form (Cochrane RR 1.27).^[5]

Medication cost comparison (2026)

Standard combination NRT protocol (8–12 weeks):

• Weeks 1–6: 21 mg patch daily + 2 mg gum or lozenge as needed for cravings (6–10 pieces/day)
• Weeks 7–8: step down to 14 mg patch + gum/lozenge PRN
• Weeks 9–10: step down to 7 mg patch + gum/lozenge PRN
• Weeks 11+: taper gum/lozenge as tolerated

Common side effects:

• Patch: skin irritation at application site (rotate sites daily), vivid or disturbing dreams (remove at bedtime if this occurs, though 24-hour wear is preferred for morning cravings)
• Gum: mouth soreness, hiccups, jaw fatigue, nausea, usually from incorrect technique. Correct technique: chew a few times until you taste peppery nicotine, then "park" the gum against your cheek for 1–2 minutes until the taste fades, then chew again. Do not chew continuously.
• Lozenge: hiccups, heartburn, nausea. Place between cheek and gum; do not chew or swallow.

"Reduce to quit" is evidence-based. For smokers who are not ready to set a hard quit date, using NRT to gradually reduce cigarette consumption doubles the eventual quit rate versus placebo (RR 2.06, BMJ meta-analysis of 2,767 patients).^[7] This is a valid entry point for ambivalent quitters.

Combination Therapy: When One Isn't Enough

Combining two mechanisms of action can produce better results than any single agent, particularly for patients who have failed a previous quit attempt on monotherapy.

Combination NRT (patch + short-acting)

The default OTC combination. Long-acting patch provides steady baseline nicotine coverage; a fast-acting form (gum, lozenge) is used for breakthrough cravings. High-certainty Cochrane evidence: RR 1.27 versus single-form NRT.^[5] Both components are OTC in the United States.

Varenicline + NRT

A 2025 meta-analysis found combination varenicline plus NRT produced higher 6-month quit rates than varenicline alone (RR 1.33, 95% CI 1.04–1.69).^[9] Adverse events were modestly higher than varenicline monotherapy but no serious adverse events increased. This is a reasonable option for patients who have failed varenicline monotherapy or who anticipate a high-difficulty quit.

Bupropion + NRT

Some evidence of additive benefit, particularly in patients with mental illness. Network meta-analyses in comorbid populations have suggested bupropion + NRT as a top-performing regimen.^[12] In practice, this combination is most useful when a patient is already on bupropion for depression and adding NRT to address cessation specifically.

Behavioral Support: The Multiplier

Medication addresses the pharmacology of nicotine addiction; behavioral support addresses the habit, the triggers, and the identity change of becoming a non-smoker. USPSTF pooled data shows the combination of medication and behavioral support has the largest effect of any intervention studied (RR 1.83 versus minimal support).^[1]

Behavioral support options are graded, evidence-based, and mostly free:

Quitlines (1-800-QUIT-NOW). Free, telephone-based coaching, operational in all 50 states. A Cochrane review of 48 RCTs found telephone counseling significantly increased long-term quit rates, with multiple proactive calls more effective than a single reactive call.^[11] Most state quitlines now include free NRT starter kits. State ROI data suggest returns of nearly $10 for every $1 invested.^[10]

Text-message programs. The CDC's SmokefreeTXT (text QUIT to 47848) and the NCI's SmokefreeVET provide daily supportive messages timed to a user-selected quit date. The seminal txt2stop RCT (n=5,800, Lancet 2011) found biochemically verified continuous abstinence at 6 months was 10.7% in the text-message arm vs 4.9% in control (RR 2.20, 95% CI 1.80–2.68).^[13]

Smartphone apps. Several evidence-based apps exist, including the NCI's quitSTART and QuitGuide, and the private-sector EX Program (Truth Initiative). Evidence for apps as monotherapy is more variable than quitlines or text programs but growing.

In-person or telehealth counseling. Structured programs based on cognitive behavioral therapy (CBT) or motivational interviewing (MI) delivered by trained counselors improve quit rates. Telehealth delivery is non-inferior to in-person for behavioral cessation support in modern RCTs.

Clinician-delivered brief counseling. Even a 3-minute conversation using the 5A model (Ask, Advise, Assess, Assist, Arrange) increases quit rates. Every clinical encounter is a legitimate cessation opportunity.

E-Cigarettes: A Nuanced Evidence Base

E-cigarettes are not FDA-approved as a smoking cessation aid, and the U.S. Preventive Services Task Force gives them an "I" (insufficient evidence) statement in its 2021 recommendation.^[1] However, the research base has grown, and a nuanced discussion is warranted.

The strongest single trial: the Hajek NEJM 2019 RCT enrolled 886 UK adults using established smoking cessation services and compared e-cigarettes with the participant's choice of NRT product. At 1 year, biochemically verified sustained abstinence was 18.0% in the e-cigarette arm versus 9.9% in the NRT arm (RR 1.83, 95% CI 1.30–2.58).^[6] Both arms received the same behavioral support.

Why USPSTF is still cautious:

• Long-term (5- to 20-year) safety data are absent
• Product heterogeneity: nicotine strength, flavoring, and device design vary widely, and results from one product may not generalize
• Dual use, patients who add e-cigarettes without eliminating combustible cigarettes may accrue harm without benefit
• Concerns about youth uptake and gateway effects at the population level

The reasonable clinical stance in 2026: e-cigarettes are not first-line. For a patient who has failed multiple courses of FDA-approved therapy and continues to smoke combustible tobacco, a full switch to e-cigarettes followed by tapering off the e-cigarette is a defensible harm-reduction strategy. Dual use should be actively discouraged.

Smoking Cessation in Special Populations

Patients with mental illness

Smokers with psychiatric illness quit at lower rates and smoke more heavily, but all three first-line medications work in this population. The EAGLES trial included a psychiatric cohort of 4,116 patients (mood, anxiety, psychotic, personality, and post-traumatic stress disorders) and found:

• Varenicline was the most effective medication in both psychiatric and non-psychiatric cohorts
• Neuropsychiatric adverse events were more common in the psychiatric cohort, but rates did not differ by medication, the events were attributable to the underlying illness, not the treatment^[3]

Post-hoc EAGLES analysis in patients with major depressive disorder found varenicline plus counseling was the best-performing option, with greater efficacy than bupropion or NRT.^[14] In practice, varenicline is preferred; bupropion is a reasonable second choice, especially if depression is also being treated.

Pregnancy

USPSTF strongly recommends behavioral interventions for pregnant patients who smoke (grade A).^[1] Pharmacotherapy in pregnancy receives an "I" statement due to limited data. Decisions are individualized, the harms of continued smoking in pregnancy are severe (preterm birth, low birth weight, stillbirth, sudden infant death syndrome), and if behavioral therapy fails, NRT is generally considered the preferred pharmacotherapy after discussion of risks and benefits with an obstetrician.

Cardiovascular disease

NRT has been extensively studied in patients with cardiovascular disease, including within days of an acute myocardial infarction, and does not increase adverse cardiac events. Varenicline and bupropion are also considered safe in stable cardiovascular disease. The relative risk of a cardiac event from continued smoking vastly exceeds any theoretical risk from cessation medication.^[2]

Adolescents

USPSTF gives an "I" statement on pharmacotherapy in adolescents due to insufficient evidence.^[1] Behavioral interventions are the mainstay. Family-based counseling and school-based programs have modest evidence. Referral to a pediatric adolescent medicine specialist is appropriate for heavy adolescent smokers.

Postoperative and hospitalized patients

Hospitalization is a "teachable moment", quit rates after a smoking-related hospitalization are higher than in ambulatory settings. Structured inpatient cessation counseling with post-discharge follow-up (at least one month) is evidence-based and now a Joint Commission quality measure.

Post-Cessation Weight Gain

Weight gain after quitting is common, expected, and a leading concern that keeps some smokers from attempting cessation. The reality:

• Mean weight gain in the first year: 4 to 10 pounds (approximately 2 to 5 kg). Some patients gain more; some do not gain at all.
• The mechanism is a combination of increased appetite (nicotine is an appetite suppressant), slowed metabolism, and behavioral compensation (snacking as substitute oral behavior).
• The cardiovascular and cancer-risk benefit of quitting vastly outweighs the health effects of modest weight gain. A 2013 NEJM analysis calculated that weight gain of 10 kg would offset only a small fraction of the cardiovascular benefit of quitting.

Practical strategies:

• Increase physical activity. Regular exercise blunts post-cessation weight gain and improves mood during withdrawal.
• Mindful eating. Watch for snacking-as-substitute-oral-behavior; keep sugar-free gum or vegetables handy.
• NRT and bupropion may modestly delay weight gain. Varenicline has minimal effect on weight during treatment.
• GLP-1 agonists, for patients who are also candidates for weight management (BMI ≥27 with comorbidities, or ≥30), a GLP-1 agonist may be considered concurrently. Small studies suggest possible additional cessation benefit but this is not yet an approved indication.

Preventing Relapse

Most quit attempts do not succeed on the first try. Population-level data suggest a median of 6 or more serious attempts before long-term abstinence. Relapse is not a failure state, it is a normal part of the process.

Predictors of relapse (all modifiable):

1. Stopping medication early. By far the most important. Complete the full 12-week course even if you feel confident.
2. High-risk situations without a plan. Alcohol, social events with other smokers, morning coffee, workplace stress. Anticipate these and script your response.
3. The "just one" belief. A single cigarette re-exposes the brain to nicotine and dramatically raises the odds of returning to daily smoking. The "not one puff" rule is not moralism; it is pharmacology.
4. Untreated depression or anxiety. Undertreated mood symptoms after quitting predict relapse. Contact a clinician early if mood symptoms persist.
5. Weight gain concerns. Address proactively (see above); do not let modest weight gain trigger a relapse.
6. Isolation. Support from family, friends, quitline coaches, or peer groups protects against relapse.

If you relapse: retry. Every serious attempt increases the odds of eventual long-term success. The medication that failed once may succeed on a second attempt, particularly if the reason for failure was medication non-adherence rather than pharmacologic ineffectiveness. Alternatively, switch to combination therapy.

What Doesn't Work

Cessation is a category where the evidence base is unusually strong, which also makes it clear which approaches lack support.

Hypnotherapy. Cochrane reviews have found insufficient evidence to recommend hypnotherapy for smoking cessation. It is not harmful, but it should not substitute for evidence-based treatment.

Acupuncture and related techniques. Cochrane meta-analyses show no clear benefit over sham control. Small effects reported in individual studies have not held up in pooled analysis.

"Detox" supplements, herbal cessation pills, and "quit smoking" homeopathic products. No credible evidence base. Products marketed for smoking cessation without FDA approval are, by definition, unregulated for content, dose, or safety.

Cigarette reduction alone (without pharmacotherapy or behavioral support). Simply cutting back rarely leads to cessation without a structured program. However, NRT-assisted reduction is evidence-based (see the "reduce to quit" strategy above).^[7]

Cold turkey without support. Willpower alone works for a small minority. The absolute quit rate from an unsupported cold-turkey attempt is roughly 3–5%. This is not a moral failing, it is the pharmacology of nicotine addiction. Every serious quit attempt should include, at minimum, either medication or behavioral support (ideally both).

Red Flags: When to Seek Immediate Medical Attention

During a quit attempt, contact a clinician promptly if you experience:

• New or worsening depression, hopelessness, or thoughts of self-harm. Nicotine withdrawal can transiently worsen mood; if symptoms are severe or persistent (>2 weeks), evaluation is needed.
• New seizure (particularly if on bupropion), stop bupropion and seek emergency evaluation.
• Severe allergic reaction to NRT, hives, facial swelling, difficulty breathing. Stop the product and seek care.
• Chest pain, arm pain, sudden shortness of breath. These may reflect cardiovascular disease unrelated to (but possibly unmasked by) the quit attempt, do not delay evaluation.
• New or worsening cough with blood-streaked sputum, or a persistent cough that does not resolve. Long-term smokers should have any new or persistent respiratory symptoms evaluated. Cough improvement over weeks is expected; new or worsening symptoms are not.
• Severe skin reaction under a nicotine patch, remove the patch; if the reaction is extensive, seek care.
• Persistent nausea or vomiting on varenicline that does not respond to taking the medication with food.

Frequently Asked Questions